Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
about
Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liverPrimary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health PerspectiveRisk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialistsPrimary biliary cirrhosis: From bench to bedsideThe diagnosis of primary biliary cirrhosisPrimary biliary cirrhosis and liver transplantationObeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selectionStratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosisBiochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.Recent advances in the management of pruritus in chronic liver diseasesBiochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients.Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008.Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic AcidHepatocyte death: a clear and present danger.The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid responsePrevention of acute kidney injury by tauroursodeoxycholic acid in rat and cell culture models.Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitisA decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.The diagnosis and treatment of primary biliary cirrhosisCXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosisAdvances in pharmacotherapy for primary biliary cirrhosis.Role of autoimmunity in primary biliary cirrhosis.Risk factors for hepatic decompensation in patients with primary biliary cirrhosisIncidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis.Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing CholangitisProposed therapies in primary biliary cholangitis.Natural history and management of primary biliary cirrhosis.A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.Von Willebrand factor and alkaline phosphatase predict re-transplantation-free survival after the first liver transplantation.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis.Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis.Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.Review article: overlap syndromes and autoimmune liver disease.Primary sclerosing cholangitis: a review and update on therapeutic developments.Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication.Primary biliary cirrhosis in adults.
P2860
Q26766699-60A2E453-7B86-422F-8F80-D48253CCB5A7Q26781780-A9A60ECF-32A6-4B30-9EC6-28077ABF73A3Q26796355-34460E67-85D9-4093-B693-7C21F10B3FA9Q26799419-768AFD90-26B7-407F-B662-D1FA1DF8B112Q26829493-AAB402F3-7D27-4F6B-B419-015EC92B8C4CQ26853145-0E44C31F-7427-479D-A76C-CD9F8DCD3EDAQ28072209-31DC0A56-4A0F-45F7-89B9-EDBB589DDD60Q33419647-D8C3774B-C2D8-461C-8A16-7A32EE240BA1Q33579196-B9E7F541-2D67-4FA5-8B91-4EA03FA59386Q33641759-EDDB77A6-29AC-454D-B347-FEFE7605AAADQ33719935-2094C0DB-8A6B-4D48-9C38-5675314B58EAQ33723821-12557D66-0FB2-4C4C-BAA4-A3B6566B7252Q33776154-FDB155D6-3A0C-4A4D-A58B-F47D5F3F51BCQ33920325-4C4F20DA-3F14-4AB0-B8A1-F66DB740A747Q34147508-C818ECF1-AB5A-442E-B068-1E79DB17CC4CQ34438127-CF81A4EA-4896-4C20-A99B-A50D971D7D33Q34477590-9D2F5146-AF77-4DD7-9FF3-BF19C6A96759Q34672135-4E0BB333-54C4-4927-85FF-68DA17D5A723Q35490131-993B639C-2995-4ABE-B0E4-85DB1FE9707DQ35637528-DA4AEBAA-BED3-4A37-9732-8AB3C5A0FB47Q35833175-AD134353-AF9A-410E-A1CF-ABAFAAF706AEQ35867125-37B83FA3-242E-4569-BF1C-3F07D8D3C4FAQ36116022-EAE78FC6-7BB8-42A0-91A0-135A119608A6Q36529131-1C9801C1-B150-408D-A925-FD1A1FE3CE2EQ36637728-C3B9CD96-1E44-4CC6-AC43-1FF49C6A612CQ36682798-D023BC3B-F095-439D-973A-5C918B4C441FQ36752084-5D820B6C-8DF3-47E4-82A1-C82978A757E3Q37072380-040A8015-419A-44A6-B322-8C233A70B2A4Q37355843-D034F0ED-959E-4279-A480-88C3BA6DECC3Q37468171-B30087B7-3688-41A0-A0D6-A6756EBF47C3Q37741829-D4A50835-1F16-423C-9F5B-2AA55D1A8C0EQ37760788-6E2FCFD5-275A-4B56-B441-223C6EA4BBE2Q37855976-909EFAE6-42A4-4292-A0EE-A5AF22766EC8Q37892296-B9E5B74B-0B8D-4608-9292-D9741334B2B5Q37963978-21F115AA-7149-4B13-9ED1-060AD9E92AD7Q38027909-C4F62508-CAC2-45A4-A4EF-DCCB4A414E7EQ38077820-F46D53FC-0EC1-43AB-BE57-E47B3A66C7E4Q38175055-C6D19993-273D-461B-BEF3-6CAF674D0257Q38183450-87E5417A-F9C5-4D34-A6F0-A4393EB0BEC6Q38192045-DEB030B3-46C7-485F-BBBB-F867E2B9CED1
P2860
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@en
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@nl
type
label
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@en
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@nl
prefLabel
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@en
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@nl
P2093
P1433
P1476
Improved prognosis of patients ...... ponse to ursodeoxycholic acid.
@en
P2093
Ben J M Witteman
Dutch PBC Study Group
Edith M M Kuiper
Els B Haagsma
Henk R van Buuren
Jannie W den Ouden-Muller
Karel J van Erpecum
Martin H M G Houben
Richard A de Vries
Theo J M van Ditzhuijsen
P304
P356
10.1053/J.GASTRO.2009.01.003
P407
P50
P577
2009-01-14T00:00:00Z